- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Gujarat Themis Biosyn (GTBL) is actively transforming into a diversified pharma platform.
**Business Performance:** GTBL's core fermentation capacity doubled to 990 KL in FY26. FY26 revenue hit INR 165.82 Cr (up from INR 150.80 Cr in FY25), though slightly below FY24. PAT for FY26 was INR 46.68 Cr, declining from previous years. EBITDA margin remained strong at 45.55%.
**Growth Drivers/Strategy:** GTBL's strategy centers on R&D innovation, forward integration into APIs, and global diversification. It aims to become a globally integrated CDMO, moving up the value chain into specialty small molecules, biologics, and gene therapy.
**Recent Developments:** Key recent moves (subject to approvals) include acquiring MicroBiopharm Japan, boosting CDMO capabilities, technical expertise (Peptides, Plasmids, ADCs), and adding JPY 9.5 Bn (INR 561.82 Cr) revenue. Also, acquiring Sanofi’s Anti-TB/Anti-Infectives portfolio for €158 mn (€62 mn CY25 sales), expanding its global reach to 59 countries and integrating into finished dosage forms.
**Management Commentary/Outlook:** Management expects these strategic acquisitions to build an integrated Intermediates-API-FDF value chain, enhance fermentation capabilities, and boost margins, positioning GTBL as a global pharma leader.